NGEN (NervGen Pharma) Moat Score: 3/10 (As of Jun. 27, 2026)


NGEN NervGen Pharma Corp NGEN
22 GF Score
Price $1.87
! 2 Warning Signs
View Full Analysis

What is NervGen Pharma Moat Score?

NervGen Pharma NGEN -1.06% 22 Moat Score is 3 as of Jun. 27, 2026. GuruFocus rates NGEN with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,404 Biotechnology companies, NervGen Pharma ranks better than 75.5% on this metric.

NervGen Pharma has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

NervGen Pharma has No Moat: NervGen Pharma Corp has potential in its R&D capabilities and intellectual property, but as a biotech firm, it faces high competition and regulatory challenges. Its advantages are currently weak and transient, not yet forming a sustainable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes NervGen Pharma might have No Moat - Very weak/transient advantages.

NervGen Pharma  (NAS:NGEN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

NervGen Pharma Moat Score Related Terms

NGEN vs CNTN, ELTX, KROS: Moat Score Comparison

For the Biotechnology subindustry, NervGen Pharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NervGen Pharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's Moat Score distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's Moat Score falls into.


NGEN
22GF Score
NervGen Pharma Corp NGEN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
NervGen Pharma (NGEN) has a Moat Score of 3 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, NervGen Pharma ranks #344 out of 1404 companies in the Biotechnology industry, placing it in the top 24.5%.
Is NervGen Pharma's Moat Score too high?
NervGen Pharma's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. NervGen Pharma's value of 3 is 50% above this industry median. Based on the distribution chart, NervGen Pharma ranks #344 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NervGen Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does NervGen Pharma's Moat Score compare to CNTN and ELTX?
According to the Biotechnology industry distribution chart, NervGen Pharma ranks #344 out of 1404 companies for Moat Score. This places NervGen Pharma in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. NervGen Pharma's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NervGen Pharma's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NervGen Pharma's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NervGen Pharma stock overvalued right now?
NervGen Pharma (NGEN) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. NervGen Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For NervGen Pharma (NGEN), the current Moat Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NervGen Pharma Business Description

Other Exchanges 9UA:Germany
Address 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
22GF Score

Get the complete analysis for NGEN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.87
Price